Will a human anti-aging drug trial with mortality or lifespan as primary endpoint be registered before 2030?
One-OffGesundheit & Medizin3JManifold MarketsKein KYCVerifizierte AuflösungsdatenGut kalibriertAktuelle Community-PrognoseNein 76.8%
Prognostiker
5
Fragetyp
binary
Methodik
Play-money forecasting platform
Quellentyp
Prognose
Marktdaten
Aktualisiert vor 16 Stunden
Veraltet1. Okt. 26, 16:22 UTC31. Dez. 29, 23:59 UTC
Trends
Regeln
Resolves YES if, before January 1, 2030, a record on ClinicalTrials.gov describes a randomized, controlled, interventional trial of a drug or biologic in humans whose stated purpose is to slow or counter aging (the record's title, brief summary, or condition field refers to aging, biological aging, lifespan, healthspan, or geroscience rather than a single disease) and whose primary outcome measure is all-cause mortality, survival, or lifespan.
- Trials in a single disease population with mortality endpoints (for example heart failure) do not count; composite disease-onset endpoints (as planned for TAME) do not count.
- Otherwise NO.
- Background: Human trials of putative anti-aging drugs have used surrogate or composite endpoints; the proposed TAME trial of metformin targets a composite of age-related diseases (Barzilai et al., Cell Metabolism 2016).
- Life-table arithmetic shows why: half of a cohort enrolled at 65 is still alive about 21 years later (WHO life tables, USA 2019), versus about 4.6 years for dogs enrolled at 8 (Teng et al., Scientific Reports 2022).
- Companion question: Will the TRIAD trial report that rapamycin significantly extended lifespan in dogs by December 31, 2031? Sources: https://doi.org/10.1016/j.cmet.2016.05.011 https://clinicaltrials.gov/ https://w0lph.github.io/k9/why-dogs.html @/w0lph/will-the-triad-trial-report-that-ra
